Autonomix Medical (NASDAQ:AMIX) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Autonomix Medical (NASDAQ:AMIX) announced its earnings results on Tuesday. The company reported ($2.51) EPS for the quarter, beating analysts’ consensus estimates of ($2.62) by $0.11, FiscalAI reports.

Autonomix Medical Stock Up 14.4%

Shares of AMIX traded up $0.24 on Tuesday, reaching $1.94. The stock had a trading volume of 57,861,297 shares, compared to its average volume of 1,541,146. The firm has a market capitalization of $1.89 million, a PE ratio of -0.05 and a beta of -0.70. The firm has a 50-day moving average of $3.32 and a 200 day moving average of $6.56. Autonomix Medical has a twelve month low of $1.46 and a twelve month high of $32.55.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Autonomix Medical in a report on Monday, October 26th. Wall Street Zen upgraded Autonomix Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $42.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.